HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $18.00 price ...
H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.
HC Wainwright decreased their Q3 2025 EPS estimates for shares of Applied Digital in a research note issued to investors on ...
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
Fintel reports that on January 17, 2025, HC Wainwright & Co. downgraded their outlook for CECO Environmental (NasdaqGS:CECO) ...
Microbot Medical Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 51.85%. The profit margin, also known as the revenue ratio or gross profit ratio, ...
H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...
H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...
RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...
https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-10-from-12-at-bofa H.C. Wainwright initiated coverage of Palvella Therapeutics ...
H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China ...